Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05645432 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05645432 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT05645432, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of brexanolone in participants with tinnitus following a single 6-hour continuous intravenous (IV) infusion.
Interventions
- DRUG Brexanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05645432
The ClinicalTrials.gov registry entry for NCT05645432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brexanolone is the first listed.
NCT05645432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05645432 about?
NCT05645432 is a clinical study titled "An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus". The primary objective of this study is to evaluate the safety and tolerability of brexanolone in participants with tinnitus following a single 6-hour continuous intravenous (IV) infusion.
What is the current status of trial NCT05645432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-05-10. Estimated completion is 2023-11-21.
What interventions are being tested in trial NCT05645432?
The interventions under investigation include: Brexanolone (DRUG).
Who is sponsoring clinical trial NCT05645432?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.